Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature
Authors:
- 4 May 2006
- journal article
- review article
- Published by Wiley in Transfusion
- Vol. 46 (5) , 741-753
Abstract
BACKGROUND: Intravenous immune globulin (IVIG) has been approved by the Food and Drug Administration (FDA) for use in 6 conditions: immune thrombocytopenic purpura (ITP), primary immunodeficiency, secondary immunodeficiency, pediatric HIV infection, Kawasaki disease, prevention of graft versus host disease (GVHD) and infection in bone marrow transplant recipients. However, most usage is for off‐label indications, and for some of these comprehensive guidelines have been published.STUDY DESIGN AND METHODS: We retrospectively reviewed all approved IVIG transfusions at Massachusetts General Hospital in 2004 to identify the current usage pattern and completed a literature review.RESULTS: IVIG was most commonly used in the treatment of chronic neuropathy, which included chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy. For such patients, the annual cost of IVIG can exceed $50,000 per patient. Other common indications were the treatment of hypogammaglobulinemia, ITP, renal transplant rejection, myasthenia gravis, Guillain‐Barre syndrome, necrotizing fasciitis, autoimmune hemolytic anemia, and Kawasaki disease. IVIG was administered in a variety of other indications each representing CONCLUSION: Only a few indications account for most of the usage for IVIG. Reports concerning IVIG continue to grow at a tremendous pace but few high‐quality randomized controlled trials have been reported. Randomized trials are especially needed for conditions such as CIDP, which consume large quantities of product.Keywords
This publication has 89 references indexed in Scilit:
- Management of Immune Thrombocytopenic Purpura in AdultsMayo Clinic Proceedings, 2004
- Clinical Experience with 20 Cases of Group A Streptococcus Necrotizing Fasciitis and Myonecrosis: 1995 to 1997Plastic and Reconstructive Surgery, 1999
- LONG-TERM BENEFIT OF INTRAVENOUS IMMUNOGLOBULINS IN CADAVERIC KIDNEY RETRANSPLANTATIONTransplantation, 1996
- Late-onset sepsis in very low birth weight neonates: A report from the National Institute of Child Health and Human Development Neonatal Research NetworkThe Journal of Pediatrics, 1996
- A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathyAnnals of Neurology, 1994
- SUPPRESSION OF HLA-SPECIFIC ALLOANTIBODIES BY HIGH-DOSE INTRAVENOUS IMMUNOGLOBULINS (IVIg)Transplantation, 1993
- Use of intravenously administered immune globulin to prevent nosocomial sepsis in low birth weight infants: Report of a pilot studyThe Journal of Pediatrics, 1989
- Experience with intravenous immunoglobulin in myasthenia gravisClinical Immunology and Immunopathology, 1989
- Intravenous Immunoglobulin for the Prevention of Infection in Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 1988
- HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA IN CHILDHOODThe Lancet, 1981